26 names are moving together; 38% are participating in the current session.
Observed intraday paths are not available for this group yet.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | Healthcare | -6.7% | Group member |
| ZENA | ZenaTech, Inc. | Technology | +1.8% | Group member |
| BRTX | BioRestorative Therapies, Inc. | Healthcare | -4.7% | Group member |
| CLRB | Cellectar Biosciences, Inc. | Healthcare | +1.1% | Group member |
| FINV | FinVolution Group | Financial Services | -4.4% | Group member |
| TTE | TotalEnergies SE | Energy | +0.4% | Group member |
| BLLN | BillionToOne, Inc. | Healthcare | -1.2% | Group member |
| WVE | Wave Life Sciences Ltd. | Healthcare | -1.3% | Group member |
| UWMC | UWM Holdings Corporation | Financial Services | +0.0% | Group member |
| CLYM | Climb Bio, Inc. | Healthcare | +1.4% | Group member |
| BKV | BKV Corporation | Energy | -4.0% | Group member |
| BETR | Better Home & Finance Holding C | Financial Services | +0.4% | Group member |
| ROKU | Roku, Inc. | Communication Services | +0.3% | Group member |
| STOK | Stoke Therapeutics, Inc. | Healthcare | -4.4% | Most structurally connected |
| EDIT | Editas Medicine, Inc. | Healthcare | -0.8% | Group member |
| BFLY | Butterfly Network, Inc. | Healthcare | -0.6% | Group member |
| TXG | 10x Genomics, Inc. | Healthcare | -1.0% | Group member |
| PSNL | Personalis, Inc. | Healthcare | -4.0% | Group member |
| HUBG | Hub Group, Inc. | Industrials | -1.6% | Group member |
| SIRI | SiriusXM Holdings Inc. | Communication Services | -0.8% | Group member |
| SUPV | Grupo Supervielle S.A. | Financial Services | +5.9% | Group member |
| IMMX | Immix Biopharma, Inc. | Healthcare | +0.6% | Group member |
| STEP | StepStone Group Inc. | Financial Services | -1.6% | Group member |
| ANAB | AnaptysBio, Inc. | Healthcare | -0.2% | Group member |
Cohort
26 namesParticipation
38% this sessionObserved history
1 daily buildsFiling coverage
22/26 memberscredit / rates affecting interest expense
“Debt subject to variable interest rates exposes the Company to variability in interest expense, while debt subject to fixed interest rates exposes the Company to variability in the fair value of debt.”
ABCL 10-K
product pipeline / R&D affecting expense
“Third-party research and development expenses were $36.0 million for the year ended December 31, 2024, compared to $33.4 million for the year ended December 31, 2025 driven by the timing of work performed primarily on our lead clinical and preclinical pipeline.”
ABCL 10-K
restructuring
“The disease is classified as a developmental and epileptic encephalopathy (DEE) due to the developmental delays and cognitive impairment associated with it.”
STOK 10-Q
Cross-asset confirmation is still fragile, so spillover can stall before it becomes durable.
No high-confidence filing-linked non-members are available for this group yet.
Historical cohort observations are not available yet.